Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The Urologic Clinics of North America|November 11, 2008
Systemic therapy for metastatic renal cell carcinomaGlenn S Kroog, Robert J Motzer
Molecular Pharmacology|September 14, 2004
Alterations in receptor expression or agonist concentration change the pathways gastrin-releasing peptide receptor uses to regulate extracellular signal-regulated kinasePei-Wen Chen, Glenn S Kroog
Cell Adhesion & Migration|June 15, 2010
Leupaxin is similar to paxillin in focal adhesion targeting and tyrosine phosphorylation but has distinct roles in cell adhesion and spreadingPei-Wen Chen, Glenn S Kroog
Ejhaem|November 10, 2025
Radiologic Pseudoprogression Associated With a Positive Response in a Patient With Multiple Myeloma Treated With a BCMA×CD3 Bispecific Antibody: A Case ReportAbdullah M Khan, Glenn S Kroog, Tito Roccia, et al.
International Journal of Radiation Oncology, Biology, Physics|October 16, 2002
Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancerMatthew M Poggi, Glenn S Kroog, Angelo Russo, et al.
Oncology and Therapy|August 4, 2024
From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare PopulationThomas E Delea, Qiufei Ma, Glenn S Kroog, et al.
Future Oncology (London, England)|February 27, 2025
Patient preferences for triple-class-exposed relapsed or refractory multiple myeloma treatment: a discrete-choice studySikander Ailawadhi, Timothy J Inocencio, Carol Mansfield, et al.
Molecular Pharmacology|September 23, 2003
Agonist- and protein kinase C-induced phosphorylation have similar functional consequences for gastrin-releasing peptide receptor signaling via GqRoxanne A Ally, Kirk L Ives, Elie Traube, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2026
Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative StudyAttaya Suvannasankha, Mengying Li, Omonefe Omofuma, et al.
Blood Advances|July 27, 2026
DISTINCT EPITOPE ENGAGEMENT CONFERS DIFFERENTIAL ACTIVITY OF LINVOSELTAMAB VERSUS TECLISTAMAB ACROSS BCMA MUTATIONSYi Zhou, Olga Sineshchekova, Ken Lee, et al.
Pageof 2